Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B.
Authors: Takeuchi M, Okimoto Y, Fukushima M, Hirano H, Ogiwara H
Journal: NPJ precision oncology
group therapy
mental health
open access